Iconovo develops ready-to-use inhalation products – inhaler devices and dry powder formulations for generic drug companies and pharmaceutical companies.
Iconovo offers a full range of ready-to-use inhalation devices to be customized with customer’s substance. We have four proprietary inhaler platforms available for customization with inhalation powder.
Iconovo is a well-established, leading Swedish company that offers innovative and effective inhalation platforms for a global market.
At Iconovo we value high quality and Scandinavian design all blended into our inhaler platforms. Our inhaler platforms meet the highest standards with innovative features, functions, and technical performance.
Possessing a unique combination of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations. We have highly skilled employees with extensive experience in developing both inhaler devices and dry powder formulations that works in our own laboratory with formulation development, inhaler customization and characterization.
Iconovo focus on the part of the value chain where it can add significant value – the development of the inhalation product, while the customer brings its expertise in performing clinical trials, manufacturing, registration and sales.
Business model: Iconovo develops the inhaler platforms at its own cost and risk and seeks patent protection for its unique designs. Iconovo develops a complete inhalation product from its customers preferred substance(s) being compensated for the development costs through development milestones.
Iconovo makes its profit from technology access fees for giving exclusive rights to a substance-inhaler combination and royalties on sales.
We offer clever and reliable products for people suffering from respiratory and other diseases to help them manage their disease and restore health. Products developed by Iconovo is mainly in the treatment of asthma and COPD, but other focus areas are
- pulmonary hypertension,
- pulmonary fibrosis
or indications where a fast onset of action is sought like migraine treatment.
The lung is also a good route of administration for peptides like insulin as peptides and proteins are broken down in the gut.
Iconovo was founded in 2013 by persons with strong background and experience in inhalation product development, entrepreneurship and industrial design. In the beginning, the Iconovo team developed a large number of device concepts and prototypes.
Today the company portfolio covers a full family of inhalation products comprising both inhalation devices and dry powder formulations.
Dr. Orest Lastow, founder of Iconovo
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
Ideon, Delta 6 Lund
SE-223 70 LUND